Caremark Rx Reports Record Second Quarter Results 36% Increase in Revenues 40% Increase in EBITDA 50% Increase in Cash Flow from Operations.Business Editors BIRMINGHAM Birmingham, cities, United States Birmingham (bûr`mĭnghăm') 1 City (1990 pop. 265,968), seat of Jefferson co., N central Ala., in the Jones Valley near the southern end of the Appalachian system; founded and inc. , Ala ALA aminolevulinic acid. Ala alanine. ala (a´lah) pl. a´lae [L.] a winglike process. .--(BUSINESS WIRE)--July 30, 2003 Caremark Rx  The introduction to this article may be too long. Please help improve the introduction by moving some material from it into the body of the article according to the suggestions at , Inc. (NYSE NYSESee: New York Stock Exchange : CMX CMX Corel Presentation Exchange (file extension) CMX Cisco Mobile Exchange CMX Cloaca Maxima (sewage system of ancient Rome; Finnish rock band) CMX Crisis Management Exercise ), one of the nation's leading pharmaceutical services companies, today reported record results for the quarter ended June June: see month. 30, 2003. For the quarter, revenues increased approximately ap·prox·i·mate adj. 1. Almost exact or correct: the approximate time of the accident. 2. 36% to $2.2 billion compared to $1.6 billion in the second quarter of 2002. EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) A metric used to show a company's profitability, but not its cash flow. EBITDA became popular in the 1980s to show the potential profitability of leveraged buyouts, but has become (earnings from continuing operations continuing operations Parts of a business that are expected to be maintained as an ongoing segment of an overall business operation. Income and losses from continuing operations are reported separately if any segments have been discontinued during the before interest, taxes, depreciation and amortization) for the quarter was $135.9 million, an increase of 40% over the $97.3 million recorded during the same period of 2002. Cash flow from continuing operations totaled $129.7 million, an increase of 50% over the $86.5 million generated during the second quarter of 2002. Operating Results - Second Quarter of 2003 During the second quarter of 2003, the company reported net revenues of $2.2 billion, a 36% increase over the second quarter of 2002. Using a 40% effective tax rate, diluted di·lute tr.v. di·lut·ed, di·lut·ing, di·lutes 1. To make thinner or less concentrated by adding a liquid such as water. 2. To lessen the force, strength, purity, or brilliance of, especially by admixture. earnings per common share increased 44% to $.26 from $.18 in the same quarter a year ago, exceeding First Call consensus estimates by $.01. Reported diluted earnings per share diluted earnings per share An earnings measure calculated by dividing net income less preferred stock dividends for a period by the average number of shares of common stock that would be outstanding if all convertible securities were converted into shares of for the second quarter of 2002 were $.27, using a 7.5% effective tax rate. Growth in both retail and mail claims as well as higher generic Generic Describes the characteristics and/or experience of the total universe of a coupon of MBS sector type; that is, in contrast to a specific pool or collateral group, as in a specific CMO issue. dispensing dispensing provision of drugs or medicines as set out properly on a lawful prescription. A prescription can only be filled, the drugs supplied, by a registered pharmacist, veterinarian, dentist or member of the medical profession. rates were drivers of the company's strong results. In the second quarter of 2003 EBITDA increased by 40% to $135.9 million from $97.3 million in the comparable quarter of 2002. EBITDA margin expanded to 6.2% compared to 6.0% in the second quarter of 2002. Operating income Operating Income The profit realized from a business' own operations. Notes: This would not include income from things such as investments in other firms. Also referred to as operating profit or recurring profit. (income from continuing operations before interest and income taxes) increased by 39% to $125.1 million from $90.0 million for the comparable quarter last year. Caremark generated $129.7 million of cash flow from operations Cash flow from operations A firm's net cash inflow resulting directly from its regular operations (disregarding extraordinary items such as the sale of fixed assets or transaction costs associated with issuing securities), calculated as the sum of net income plus noncash expenses for the quarter ended June 30, 2003, compared with $86.5 million in the same quarter last year, an increase of 50%. As of June 30, 2003, the company's cash balance was $525.8 million and net debt was $171.1 million, a reduction of $126.4 million since March 31, 2003. Mail pharmacy pharmacy, art of compounding and dispensing drugs and medication. The term is also applied to an establishment used for such purposes. Until modern times medication was prepared and dispensed by the physician himself. In the 18th cent. prescriptions increased to 6.1 million during the second quarter of 2003, an increase of 25% over the same period in the prior year. Retail claims totaled 22.1 million during the second quarter, representing a 29% increase over the second quarter of 2002. Mail order prescriptions represented 22% of all prescriptions processed during the second quarter, or 45% of all prescriptions processed on a retail-adjusted basis. Caremark's mail generic dispensing rate increased to 35.1% in the second quarter of 2003 compared to 32.2% in the comparable period last year. The company's retail generic dispensing rate was 45.0%, up from 42.4% in the second quarter of 2002. Six Month Results Net revenues for the six months ending June 30, 2003 were $4.4 billion, a 35% increase over the same period in the prior year. Using a 40% effective tax rate, diluted earnings per common share for the first six months of 2003 increased 52% to $.50 compared to $.33 for the first half of 2002. Reported diluted earnings per share for the first half of 2002 were $.51 using a 7.5% effective tax rate. EBITDA increased by 42% to $261.8 million from $183.8 million, and operating income increased by 42% to $241.2 million from $169.8 million for the comparable six month period last year. In addition, the Company's EBITDA margin increased to 6.0% compared with 5.7% in the prior period. The Company's cash flow from operations for the first half of 2003 totaled $267.4 million as compared with $186.9 million during the same period of 2002, an increase of 43%. At June 30, 2003, Caremark's net debt had decreased by $220.2 million since December December: see month. 31, 2002. During the first half of 2003, mail pharmacy prescriptions totaled 12.1 million, an increase of 23% over the same period last year. Retail claims totaled 44.3 million during the first half of 2003, representing a 27% increase over the same period of 2002. For the six months ended June 30, 2003, mail order prescriptions represented 21% of all prescriptions processed, or 44% of all prescriptions processed on a retail-adjusted basis. Commenting on this quarter's results, Mac Crawford, Chairman of the Board and Chief Executive Officer of Caremark Rx, Inc. said, "The company performed well in the second quarter as we experienced strong growth in all product lines, and our generic dispensing rates continue to increase, providing benefits to our clients. Our cash flow has allowed us to continue to strengthen our balance sheet." Guidance Update The Company expects 2003 diluted earnings per share to be in a range of $1.06 to $1.08, up from a previous range of $1.02 to $1.04 with revenue growth for the year expected to exceed 30%. Conference Call As announced, Caremark will hold a conference call to discuss second-quarter earnings. The details of the call are as follows: Date: Wednesday, July 30, 2003 Time: 10:30 a.m. Eastern Time Toll Number: (913) 981-5548 Toll-Free Number: (800) 289-0488 Leader: Mac Crawford Replay Number: (719) 457-0820 Passcode: 526407 The call will also be broadcast live as well as replayed through the Internet Internet Publicly accessible computer network connecting many smaller networks from around the world. It grew out of a U.S. Defense Department program called ARPANET (Advanced Research Projects Agency Network), established in 1969 with connections between computers at the . The webcast can be accessed through the "Investor Information" page on the Caremark Rx, Inc. website at www.caremarkrx.com. A taped replay of the call will also be available beginning at 1:30 p.m. Eastern Time on Wednesday Wednesday: see week. , July July: see month. 30, 2003, until 6:00 p.m. Eastern Time, Wednesday, August 6, 2003, by calling the replay number listed above. About Caremark Rx, Inc. Caremark Rx, Inc. is a leading pharmaceutical services company, providing comprehensive drug benefit services through its affiliate Affiliate Relationship between two companies when one company owns substantial interest, but less than a majority of the voting stock of another company, or when two companies are both subsidiaries of a third company. See: Subsidiaries, parent company. Caremark Inc. to over 1,200 health plan sponsors and their participants throughout the U.S. Caremark's clients include corporate health plans, managed care organizations, insurance companies, unions, government agencies and other funded benefit plans. The company operates a national retail pharmacy network with over 55,000 participating pharmacies This article is a list of major pharmacies (also known as chemists and drugstores) by country. Australia Pharmacies in Australia are mostly independently-owned by pharmacists, often operated as franchises of retail brands offered by the three major , four state-of-the-art mail service pharmacies, the industry's only FDA-regulated repackaging plant and nineteen specialty A contract under seal. A specialty is a written document that has been sealed and delivered and is given as security for the payment of a specifically indicated debt. distribution mail service pharmacies for delivery of advanced medications to individuals with chronic or genetic diseases and disorders A
Forward-Looking Statement forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. This press release contains statements that constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934 as amended a·mend v. a·mend·ed, a·mend·ing, a·mends v.tr. 1. To change for the better; improve: amended the earlier proposal so as to make it more comprehensive. 2. by the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. "Forward-looking statements" contained in this press release include the intent, belief or current expectations of the company and members of its senior management team with respect to the anticipated growth prospects for the company's business, including earnings per share projections and expected revenues for the company in 2003, as well as the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those contemplated by the forward-looking statements in this press release include, but are not limited to, adverse developments with respect to the company's operating plan and objectives, as well as adverse developments in the healthcare or pharmaceutical industry generally. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2002. This presentation includes certain non-GAAP financial measures as defined under SEC rules. As required by SEC rules, we have provided, in the footnotes to the tables attached hereto here·to adv. To this document, matter, or proposition. hereto Adverb Formal or law to this place, matter, or document Adv. 1. , a reconciliation of those measures to the most directly comparable GAAP GAAP See: Generally Accepted Accounting Principles GAAP See generally accepted accounting principles (GAAP). measures. Additional information about Caremark Rx is available on the World Wide Web at http://www.caremarkrx.com
CAREMARK RX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
June 30, December 31,
2003 2002
------------ ------------
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 525,778 $ 306,804
Accounts receivable, net 569,748 506,919
Inventories 151,179 200,412
Deferred tax asset, net 196,934 201,738
Prepaid expenses and other current assets 14,583 9,772
------------ ------------
Total current assets 1,458,222 1,225,645
Property and equipment, net 144,142 139,002
Intangible assets, net 60,260 61,604
Deferred tax asset, net 355,563 412,588
Other assets 72,019 73,901
------------ ------------
Total assets $ 2,090,206 $ 1,912,740
============ ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 310,009 $ 294,758
Claims and discounts payable 405,663 370,031
Other accrued expenses and liabilities 153,901 180,685
Income taxes payable 3,675 3,409
Current portion of long-term debt 2,500 2,500
Current liabilities of discontinued
operations - 25,622
------------ ------------
Total current liabilities 875,748 877,005
Long-term debt, net of current portion 694,375 695,625
Other long-term liabilities 80,970 82,417
------------ ------------
Total liabilities 1,651,093 1,655,047
Commitments and contingencies
Stockholders' equity:
Common stock 267 263
Additional paid-in capital 1,720,150 1,665,155
Treasury stock (28,782) (22,671)
Shares held in trust (101,963) (102,948)
Accumulated deficit (1,140,524) (1,272,071)
Accumulated other comprehensive loss (10,035) (10,035)
------------ ------------
Total stockholders' equity 439,113 257,693
------------ ------------
Total liabilities and stockholders'
equity $ 2,090,206 $ 1,912,740
============ ============
CAREMARK RX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(In thousands, except per share amounts)
Three Months Ended Six Months Ended
June 30, June 30,
----------------------- -----------------------
2003 2002 2003 2002
----------- ----------- ----------- -----------
Net revenue $2,204,039 $1,626,466 $4,367,835 $3,240,583
Operating expenses:
Cost of revenues* 2,019,399 1,488,061 4,011,100 2,978,911
Selling, general and
administrative
expenses 48,785 41,075 94,888 77,917
Depreciation and
amortization 10,758 7,311 20,634 14,003
----------- ----------- ----------- -----------
Operating income
(EBIT) 125,097 90,019 241,213 169,752
Interest expense, net 10,875 11,645 21,969 23,816
----------- ----------- ----------- -----------
Income before
provision for income
taxes 114,222 78,374 219,244 145,936
Provision for income
taxes (1) 45,688 5,878 87,697 10,945
----------- ----------- ----------- -----------
Net income 68,534 72,496 131,547 134,991
Preferred security
dividends (2) - 3,305 - 6,609
----------- ----------- ----------- -----------
Net income to common
stockholders $ 68,534 $ 69,191 $ 131,547 $ 128,382
=========== =========== =========== ===========
Average number of
common shares
outstanding - basic 256,391 228,115 255,864 227,473
Dilutive effect of
stock options 7,215 10,930 6,832 10,650
Convertible Preferred
Securities (2) - 26,850 - 26,850
----------- ----------- ----------- -----------
Average number of
common shares
outstanding - diluted 263,606 265,895 262,696 264,973
=========== =========== =========== ===========
Net income per common
share - diluted $ 0.26 $ 0.27 $ 0.50 $ 0.51
=========== =========== =========== ===========
Supplemental presentation
of non-GAAP financial measures:
Net income per common
share - diluted (at
40% effective income
tax rate) (1) $ 0.26 $ 0.18 $ 0.50 $ 0.33
=========== =========== =========== ===========
EBITDA (Earnings
before interest,
taxes, depreciation
and amortization) (3) $ 135,855 $ 97,330 $ 261,847 $ 183,755
=========== =========== =========== ===========
* Excludes depreciation which is presented separately. See note 5.
CAREMARK RX, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
Six Months Ended
June 30,
-------------------
2003 2002
--------- ---------
Cash flows from continuing operations:
Net income $131,547 $134,991
Adjustments to reconcile net income to net cash
provided by
continuing operations:
Deferred income taxes 78,058 -
Depreciation and amortization 20,634 14,003
Non-cash interest expense 1,804 1,597
Other non-cash expenses 541 -
Changes in operating assets and liabilities, net
of effects of
acquisitions of businesses 34,807 36,344
--------- ---------
Net cash provided by continuing operations 267,391 186,935
Cash flows from investing activities:
Capital expenditures, net (26,589) (13,881)
Acquisitions of business, net of cash acquired (319) (49,039)
--------- ---------
Net cash used in investing activities (26,908) (62,920)
Cash flows from financing activities:
Net proceeds from exercise/retirement of stock
options and warrants 39,214 14,618
Purchase of treasury stock (6,111) -
Net proceeds (repayments) under credit facility (1,250) 1,250
Long-term debt issuance costs (100) (1,230)
Net repayments under trade receivables sales
facility - (99,200)
Dividend payments on Convertible Preferred
Securities - (7,000)
--------- ---------
Net cash provided by (used in) financing
activities 31,753 (91,562)
Cash used in discontinued operations (53,262) (20,980)
--------- ---------
Net increase in cash and cash equivalents 218,974 11,473
Cash and cash equivalents - beginning of period 306,804 159,066
--------- ---------
Cash and cash equivalents - end of period $525,778 $170,539
========= =========
CAREMARK RX, INC. AND SUBSIDIARIES
SELECTED STATISTICS AND RATIOS
(In millions, expect per adjusted claim amounts)
Three Months Ended
June 30, Percentage
-----------------------
2003 2002 Increase
----------- ----------- -----------
Claims Processed
Mail 6.1 4.9 25%
Retail 22.1 17.2 29%
---------- ---------- -----------
Total 28.2 22.1 28%
========== ========== ===========
Adjusted Claims (4) 40.1 31.6 27%
========== ========== ===========
Per Adjusted Claim
Gross Profit (excluding
depreciation) (5) $ 4.61 $ 4.38 5%
========== ========== ===========
EBITDA (3) $ 3.39 $ 3.08 10%
========== ========== ===========
Six Months Ended
June 30, Percentage
-----------------------
2003 2002 Increase
----------- ----------- -----------
Claims Processed
Mail 12.1 9.8 23%
Retail 44.3 35.0 27%
----------- ----------- -----------
Total 56.4 44.8 26%
=========== =========== ===========
Adjusted Claims (4) 79.8 63.7 25%
=========== =========== ===========
Per Adjusted Claim
Gross Profit (excluding
depreciation) (5) $ 4.47 $ 4.11 9%
=========== =========== ===========
EBITDA (3) $ 3.28 $ 2.88 14%
=========== =========== ===========
June 30, December 31,
2003 2002
----------- -----------
Balance Sheet Debt
Term Loans $ 246.9 $ 248.1
Senior Notes 450.0 450.0
----------- -----------
Total 696.9 698.1
Cash and cash equivalents 525.8 306.8
----------- -----------
Net Debt (6) $ 171.1 $ 391.3
=========== ===========
LTM EBITDA (7) $ 488.6 $ 410.5
=========== ===========
Net Debt to LTM EBITDA (6)(7) 0.4x 1.0x
=========== ===========
(1) In the fourth quarter of 2002, we reduced the valuation allowance
on our net deferred income tax asset to reflect a change in
management's assessment of the amount expected to be utilized to
offset future amounts of taxable income. This change resulted in
our recording the provision for income taxes at different rates in
the 2003 (40%) and 2002 (7.5%) periods presented above; however,
there was no impact on the actual taxes we expect to pay. We have
included a non-GAAP calculation of 2002 earnings per share as if
we had reduced this valuation allowance prior to 2002 to enable
investors to more easily compare earnings per share for the
periods presented above. GAAP net income per common share -
diluted can be reconciled to this measure as follows:
Three Months Ended Six Months Ended
June 30, June 30,
--------------------- -------------------
2003 2002 2003 2002
--------- --------- --------- ---------
Net income per
common share - diluted $ 0.26 $ 0.27 $ 0.50 $ 0.51
Incremental tax
provision per diluted
common share N/A (0.09) N/A (0.18)
--------- --------- --------- ---------
Net income per common
share - diluted
(at 40% effective
income tax rate) $ 0.26 $ 0.18 $ 0.50 $ 0.33
========= ========= ========= =========
(2) Our Convertible Preferred Securities were presumed to have been
converted to common stock at the beginning of the 2002 period
under the "if-converted" method of computing common stock
equivalents. In October 2002, these Convertible Preferred
Securities were converted into 26,850,000 shares of common stock.
This conversion had no impact on the number of shares included in
the average number of common shares outstanding - diluted for
either period.
(3) We believe that EBITDA is a supplemental measurement tool used by
analysts and investors to help evaluate a company's overall
operating performance; its ability to incur and service debt and
its capacity for making capital expenditures. We use EBITDA, in
addition to operating income and cash flows from operating
activities, to assess our performance and believe that it is
important for investors to be able to evaluate our company using
the same measures used by our management. EBITDA can be reconciled
to net cash provided by continuing operations, which we believe to
be the most directly comparable financial measure calculated and
presented in accordance with GAAP, as follows (in thousands):
Three Months Ended Six Months Ended
June 30, June 30,
---------------------- ----------------------
2003 2002 2003 2002
---------- --------- ---------- ---------
Operating income
(EBIT) $ 125,097 $ 90,019 $ 241,213 $169,752
Depreciation and
amortization 10,758 7,311 20,634 14,003
---------- --------- ---------- ---------
EBITDA 135,855 97,330 261,847 183,755
Cash interest payments,
net of interest income (19,945) (18,925) (21,727) (22,149)
Cash tax payments,
net of refunds (2,915) (699) (9,368) (3,642)
Other non-cash expenses 144 -- 541 --
Other changes in
operating assets and
liabilities, net of
acquisitions and
disposals of businesses 16,520 8,776 36,098 28,971
---------- --------- ---------- ---------
Net cash provided by
continuing operations $ 129,659 $ 86,482 $ 267,391 $186,935
========== ========= ========== =========
EBITDA does not represent funds available for our discretionary
use and is not intended to represent or to be used as a substitute
for net income or cash flow from operations data as measured under
GAAP. The items excluded from EBITDA are significant components of
our statement of operations and must be considered in performing a
comprehensive assessment of our overall financial performance.
EBITDA and the associated year-to-year trends should not be
considered in isolation. Our calculation of EBITDA may not be
consistent with calculations of EBITDA used by other companies.
(4) Adjusted pharmacy claims normalize the claims volume statistic for
the difference in 90-days' supply for mail claims and 30-days'
supply for retail claims. Adjusted pharmacy claims are calculated
by multiplying 90-day claims by 3 and adding the 30-day claims to
the product.
(5) We have historically excluded depreciation from our cost of
revenues and, hence, from our computation of Gross Profit (net
revenue minus cost of revenues); however, SEC rules require the
inclusion of depreciation expense in gross profit. Therefore, the
amount of Gross Profit used to compute the Gross Profit per
adjusted claim statistic presented above is a non-GAAP measurement
as defined by the SEC's Regulation G. Our management measures our
results of operations using both EBITDA (see note 3 above) and
cash flows from operating activities, both of which exclude
depreciation, and with Operating Income (EBIT), which includes
depreciation. As previously mentioned, we believe that it is
important for investors to be able to evaluate our company using
the same measures used by our management; therefore, we have used
our internal calculation of Gross Profit to compute the Gross
Profit per adjusted claim statistic above. This amount reconciles
to gross profit calculated under SEC rules (GAAP gross profit) as
follows (in thousands except per adjusted claim amounts):
Three Months Ended Six Months Ended
June 30, June 30,
----------------------- ----------------------
2003 2002 2003 2002
----------- ----------- ----------- ----------
Net revenue $2,204,039 $1,626,466 $4,367,835 $3,240,583
Cost of revenues
(excluding depreciation
expense) 2,019,399 1,488,061 4,011,100 2,978,911
----------- ----------- ----------- ----------
Gross Profit 184,640 138,405 356,735 261,672
Depreciation expense
allocated to cost of
revenues 9,318 6,010 17,919 11,414
----------- ----------- ----------- ----------
GAAP gross profit $ 175,322 $ 132,395 $ 338,816 $ 250,258
----------- ----------- ----------- ----------
GAAP gross profit
per adjusted claim $ 4.37 $ 4.19 $ 4.25 $ 3.93
=========== =========== =========== ==========
(6) Net debt is a non-GAAP financial measure and equals total
indebtedness minus cash and cash equivalents. We use net debt as
the numerator in our "net debt to LTM EBITDA" ratio, which is the
primary coverage ratio reviewed by management, in order to reflect
the availability of the cash and cash equivalents on our balance
sheet for use in debt service.
(7) LTM EBITDA is a non-GAAP financial measure representing our EBITDA
generated in the last twelve months. We use LTM EBITDA as the
denominator in our "net debt to LTM EBITDA" coverage ratio to
reflect management's view of our capacity to service debt. LTM
EBITDA is subject to all of the limitations concerning our
presentation of EBITDA described in note 3 above. LTM EBITDA can
be reconciled to net cash provided by continuing operations over
the last twelve months, which we believe to be the most directly
comparable financial measure calculated and presented in
accordance with GAAP, as follows (in thousands):
Twelve Months Ended
-------------------
June 30, Dec. 31,
2003 2002
--------- ---------
Operating income (EBIT) $452,063 $380,602
Depreciation and amortization 36,559 29,928
--------- ---------
EBITDA 488,622 410,530
Cash interest payments, net of interest income (42,945) (43,367)
Cash tax payments, net of refunds (12,844) (7,118)
Other non-cash expenses 1,604 1,063
Other changes in operating assets and liabilities,
net of acquisitions and disposals of businesses 54,450 47,323
--------- ---------
Net cash provided by continuing operations $488,887 $408,431
========= =========
|
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion